Major Study: High-Dose EPA Slashes Cardiovascular Risk
A major study, the REDUCE-IT trial, has shown that a high dose of purified eicosapentaenoic acid (EPA) significantly reduces cardiovascular events in high-risk patients. This has led to regulatory approvals and guideline updates for prescription EPA. A recent meta-analysis further supports the role of omega-3 fatty acids in cardiovascular health.
The REDUCE-IT trial in 2018 demonstrated that EPA alone was more effective in reducing cardiovascular risk compared to EPA combined with docosahexaenoic acid (DHA). This is likely due to the different chemical properties of EPA and DHA, which influence their effects on cholesterol molecules and cell membranes.
A systematic review and meta-analysis of 38 randomized controlled trials found that omega-3 fatty acids improve cardiovascular outcomes, reducing cardiovascular mortality and improving overall heart health. This has led to FDA, Health Canada, and EMA approval of icosapent ethyl for reducing cardiovascular risk, and updates to global guidelines. Further research is encouraged to explore the cardiovascular effects of EPA across different clinical settings.
The REDUCE-IT trial and subsequent meta-analysis provide strong evidence for the use of prescription EPA in reducing cardiovascular risk. While DHA alone has not been studied, EPA's beneficial anti-inflammatory and lipid-lowering effects are well-established. Further research will continue to explore the potential of EPA in various clinical settings.
